Friday, 19 August 2016

CAR T cell therapy for diffuse large B cell lymphoma included in EMA’s priority medicines scheme

The European Medicines Agency (EMA) has released, on 1 June 2016, the outcome of the assessment of the first batch of applications received from medicine developers for its PRIME (PRIority MEdicines) scheme, a new initiative that aims to foster research on and development of medicines that have the potential to address an unmet medical need.

The names of the four active substances that will benefit from PRIME support are also released. The first four PRIME candidates are: Biogen’s aducanumab, a beta-amyloid targeting antibody for Alzheimer disease; Kite Pharma’s KTE-C19, a chimeric antigen receptor (CAR) T cell therapy for diffuse large B cell lymphoma; ChemoCentryx’s CCX168, a C5a receptor inhibitor for ANCA-associated vasculitis; and Novoimmune’s NI-0501, an interferon-γ antibody for the rare autoimmune disease haemophagocytic lymphohistiocytosis.

Read more here.

No comments:

Post a Comment